

Anne Mary Noonan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1477494/publications.pdf>

Version: 2024-02-01

79
papers

1,732
citations

318942

23
h-index

355658

38
g-index

79
all docs

79
docs citations

79
times ranked

3472
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Follow-Up of Fractional CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors. <i>Journal of Clinical Medicine</i> , 2022, 11, 774.	1.0	10
2	The impact of germline and somatic mutations in the homologous recombination repair pathway in pancreatic cancer patients who undergo perioperative chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 602-602.	0.8	0
3	Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer. <i>Cells</i> , 2022, 11, 910.	1.8	4
4	EPR22-106: Decelerating Decline and Urban-Rural Differences for Gastrointestinal Cancer Mortality in the United States, 1999-2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, EPR22-106.	2.3	0
5	Breast cancer survivors' typhoid vaccine responses: Chemotherapy, obesity, and fitness make a difference. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 1-9.	2.0	5
6	S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15007-e15007.	0.8	0
7	The impact of HRD in patients with pancreatic adenocarcinoma undergoing surgical resection: An updated analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4132-4132.	0.8	0
8	A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15059-e15059.	0.8	0
9	Primary care physician's confidence and coordination regarding the survivorship care for older breast cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 223-230.	1.0	8
10	Worry and rumination in breast cancer patients: perseveration worsens self-rated health. <i>Journal of Behavioral Medicine</i> , 2021, 44, 253-259.	1.1	19
11	Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. <i>Menopause</i> , 2021, 28, 642-649.	0.8	22
12	A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	9
13	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	2.0	16
14	Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2803-2815.	0.8	58
15	Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5168.	1.7	1
16	Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience. <i>The Journal of Breast Health</i> , 2021, 17, 371-377.	0.4	4
17	In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors. <i>Pharmaceutics</i> , 2021, 13, 2004.	2.0	9
18	Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	56

#	ARTICLE	IF	CITATIONS
19	Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 33-40.	1.1	30
20	Primary care physicians' perspectives of the survivorship care for older breast cancer survivors: a pilot study. <i>Supportive Care in Cancer</i> , 2020, 28, 645-652.	1.0	13
21	Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 384-396.	1.9	18
22	Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 3669-3677.	1.0	29
23	Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3784.	1.7	3
24	Perspectives of Survivorship Care Plans Among Older Breast Cancer Survivors: A Pilot Study. <i>Cancer Control</i> , 2020, 27, 107327482091720.	0.7	12
25	Neoadjuvant modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. <i>Cancer Medicine</i> , 2020, 9, 4711-4723.	1.3	28
26	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. <i>Gene Expression</i> , 2020, 20, 53-65.	0.5	65
27	Metastatic breast cancer patient perceptions of somatic tumor genomic testing. <i>BMC Cancer</i> , 2020, 20, 389.	1.1	8
28	Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. <i>Hpb</i> , 2020, 22, 1569-1576.	0.1	22
29	Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice. <i>BMC Geriatrics</i> , 2020, 20, 231.	1.1	36
30	CD200 promotes immunosuppression in the pancreatic tumor microenvironment. , 2020, 8, e000189.		52
31	Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience. <i>Investigational New Drugs</i> , 2020, 38, 1605-1611.	1.2	2
32	Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. <i>Journal of Clinical Investigation</i> , 2020, 130, 4601-4606.	3.9	44
33	A pilot study of Bruton's tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor nivolumab in patients with metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3111-3111.	0.8	4
34	Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls. <i>The Journal of Breast Health</i> , 2020, 16, 201-207.	0.4	3
35	CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 746-746.	0.8	0
36	Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00271.	1.3	7

#	ARTICLE	IF	CITATIONS
37	Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 941-949.	1.9	25
38	Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. <i>Medical Oncology</i> , 2019, 36, 87.	1.2	12
39	Association of Liver-Directed Local Therapy With Overall Survival in Adults With Metastatic Intrahepatic Cholangiocarcinoma. <i>JAMA Network Open</i> , 2019, 2, e1911154.	2.8	12
40	ASCO gastrointestinal cancers symposium: Perspectives on older adults with gastrointestinal malignancies. <i>Journal of Geriatric Oncology</i> , 2019, 10, 371-373.	0.5	0
41	Physical Activity After Breast Cancer Surgery: Does Depression Make Exercise Feel More Effortful than It Actually Is?. <i>International Journal of Behavioral Medicine</i> , 2019, 26, 237-246.	0.8	11
42	Significant and Durable Clinical Response to Sorafenib and Radiation Therapy for a Patient With Stage IV Hepatocellular Carcinoma and LRRK2 Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	1
43	Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. <i>Pancreatology</i> , 2019, 19, 80-87.	0.5	24
44	A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology. <i>Clinical Breast Cancer</i> , 2019, 19, 89-96.	1.1	13
45	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3704-3721.	1.4	107
46	Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1 α in advanced hepatocellular carcinoma. <i>World Journal of Clinical Oncology</i> , 2019, 10, 149-160.	0.9	30
47	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2018, 78, 5398-5407.	0.4	20
48	Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4110-4110.	0.8	11
49	Meta-analysis to identify emerging biomarkers of pancreatic adenocarcinoma pathogenesis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16239-e16239.	0.8	0
50	Comprehensive Geriatric Assessment in Oncology: Best Practices in Caring for Older Patients. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 640-644.	0.2	3
51	A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 75-82.	1.4	46
52	A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3541-3541.	0.8	53
53	Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12126-e12126.	0.8	0
54	Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10102-10102.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).. Journal of Clinical Oncology, 2017, 35, TPS1127-TPS1127.	0.8	0
56	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	3.7	114
57	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. Medical Oncology, 2016, 33, 48.	1.2	20
58	Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer, 2016, 122, 3657-3666.	2.0	41
59	Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecologic Oncology, 2016, 142, 332-340.	0.6	85
60	Pharmacodynamic markers and clinical results from the phase 2 study of the <scp>SMAC</scp> mimetic birinapant in women with relapsed platinum-resistant or refractory epithelial ovarian cancer. Cancer, 2016, 122, 588-597.	2.0	77
61	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 2565-2574.	3.2	80
62	Next Generation Sequencing (NGS) to reveal mutations in IDH1 and its effect on patient (pt) outcomes in advanced biliary tract cancer (aBTC) who received gemcitabine and cisplatin (GC).. Journal of Clinical Oncology, 2016, 34, 287-287.	0.8	0
63	Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience.. Journal of Clinical Oncology, 2016, 34, 584-584.	0.8	0
64	Comprehensive analysis of radiographic, clinical, and inflammatory markers demonstrating changes in lean muscle correlate with outcome in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) who undergo taxane-based chemotherapy (CT).. Journal of Clinical Oncology, 2016, 34, 349-349.	0.8	0
65	Irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): A single institution experience.. Journal of Clinical Oncology, 2016, 34, 215-215.	0.8	0
66	Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience.. Journal of Clinical Oncology, 2016, 34, 4100-4100.	0.8	0
67	Next-generation sequencing (NGS) survey of biliary tract cancer (BTC) to reveal the association between tumor somatic variants and chemotherapy resistance.. Journal of Clinical Oncology, 2016, 34, 4079-4079.	0.8	18
68	Second-line outcomes in metastatic colorectal cancer – raising the bar for the high jump rather than the doing the limbo. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 133-143.	0.7	2
69	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. Oncotarget, 2015, 6, 22206-22213.	0.8	7
70	Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses. Journal of the National Cancer Institute, 2014, 106, dju089.	3.0	161
71	Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived) Tj ETQq1 1 0.784314 rgBT /Overlock ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368).. Journal of Clinical Oncology, 2014, 32, 5585-5585.	0.8	3
72	Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel. Clinical Cancer Research, 2013, 19, 3095-3104.	3.2	43

#	ARTICLE	IF	CITATIONS
73	Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. <i>Cancer</i> , 2013, 119, 1357-1364.	2.0	24
74	Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2514-2514.	0.8	6
75	RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox”Reply to Point. <i>Cancer Research</i> , 2012, 72, 5150-5150.	0.4	2
76	IKK- μ Coordinates Invasion and Metastasis of Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 5494-5504.	0.4	45
77	Why RECIST Works and Why It Should Stay”Counterpoint. <i>Cancer Research</i> , 2012, 72, 5151-5157.	0.4	28
78	Feasibility and safety of sequential research-related tumor core biopsies in clinical trials with anti-angiogenic and targeted therapies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2545-2545.	0.8	11
79	Distress Disorder Histories Relate to Greater Physical Symptoms Among Breast Cancer Patients and Survivors: Findings Across the Cancer Trajectory. <i>International Journal of Behavioral Medicine</i> , 0, , .	0.8	0